Log In
Print this Print this

vanucizumab (RG7221)

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionBispecific mAb targeting VEGF and angiopoietin 2 (ANG2; ANGPT2)
Molecular Target Angiopoietin 2 (ANG2) (ANGPT2) ; Vascular endothelial growth factor (VEGF)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationColorectal cancer
Indication DetailsTreat colorectal cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today